Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARASOL: Sacubitril/Valsartan vs amlodipine in essential hypertension
jRCTs051220165Completed
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sacubitril + valsartan in essential hypertension (2 arms), sponsored by Novartis. Primary endpoint: Change in 24-hour systolic blood pressure from baseline to Week 8. Started Feb 2023; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCTs051220165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220165.